NASDAQ
1.97USD
+0.05 (+2.60%)
We have scored 4 news catalysts on NervGen Pharma Corp. Common stock (NGEN) over the past 12 months. The biggest single-day move next to one of them came Mar 17, 2026, when NGEN closed +4.9%: “NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade)”. Coverage across the window leans positive (average ticker sentiment +0.45). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
161.5M
P/E
—
EPS
—
Beta
0.73
52W range
1.58-6.3
Day range
1.90–1.98
Open
1.91
Prev close
1.92
Volume
96.3K
Avg volume
830.9K
Dividend
0.00
IPO
2021-02-08
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about NervGen Pharma Corp. Common stock — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NGEN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
